Altus Pharmaceuticals Inc. And Dr. Falk Pharma GmbH Announce TheraCLEC Granted Orphan Drug Designation By The European Medicines Evaluation Agency
10/19/2005 5:11:48 PM
Altus Pharmaceuticals Inc. and Dr. Falk Pharma GmbH announced today that TheraCLEC(TM) was granted orphan drug designation by the European Medicines Evaluation Agency (EMEA). TheraCLEC was granted designation for the treatment of malabsorption due to exocrine pancreatic insufficiency, a condition most often found in patients suffering from cystic fibrosis (CF), chronic pancreatitis (CP), pancreatic cancer as well as other diseases where the pancreas is not producing sufficient amounts of endogenous enzymes required for proper nutrition.
comments powered by